FIELD: immunology.
SUBSTANCE: invention relates to immunology. Disclosed is a method for treating urothelial carcinoma which involves the introduction to the subject of a therapeutically effective quantity of the inhibitor of the interaction of the receptor PD-1 and the ligand PD-L1 thereof, where the inhibitor is an antibody against PD-L1, such as avelumab.
EFFECT: invention enables effective treatment of urothelial carcinoma.
13 cl, 2 dwg, 17 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PD-1/PD-L1 INHIBITORS FOR TREATING CANCER | 2016 |
|
RU2714233C2 |
| USE OF ANTI-PD-1 ANTIBODY IN PREPARATION OF MEDICINAL AGENT FOR TREATING SOLID TUMOURS | 2020 |
|
RU2825845C2 |
| COMBINATION OF POXVIRUS ENCODING HUMAN PAPILLOMA VIRUS POLYPEPTIDES, AND IL-2 WITH ANTI-PD-L1 ANTIBODY | 2020 |
|
RU2824962C1 |
| COMBINATION OF PD-1 ANTAGONIST AND IDO1 INHIBITOR FOR TREATING ANCER | 2015 |
|
RU2744880C1 |
| COMBINATION OF ANTI-PD-L1 ANTIBODY AND DNA-PK INHIBITOR FOR TREATING MALIGNANT NEOPLASM | 2018 |
|
RU2765997C2 |
| COMBINED METHODS FOR TREATING WITH PD-L1 ANTAGONISTS | 2016 |
|
RU2766890C2 |
| ANTIBODIES AGAINST PD-1 FOR TREATMENT OF LUNG CANCER | 2018 |
|
RU2771759C2 |
| TREATING LUNG CANCER BY COMBINATION OF ANTI-PD-1 AND OTHER ANTI-CANCER AGENTS | 2015 |
|
RU2695332C2 |
| COMBINATION OF HDAC INHIBITOR AND ANTI-PD-1 ANTIBODY FOR TREATMENT OF CANCER | 2016 |
|
RU2796903C2 |
| METHODS OF TREATING CANCER USING ANTI-PD-1 ANTIBODIES AND ANTI-CTLA4 ANTIBODIES | 2019 |
|
RU2825835C2 |
